OUR EXPERIENCE IN APPLICATION OF AUTOLOGOUS BONE-MARROW-DERIVED MESENCHYMAL STEM CELLS FOR THERAPY OF PATIENTS WITH SYMPTOMATIC EPILEPSY
Abstract
Abstract: an article presented the data on application of autologous multipotent mesenchymal stem cells (MMSCs) from bone marrow for therapy of 10 patients suffering from drug-resistant symptomatic epilepsy. Intravenous injection of 40.0-101.0Ч106 (mean 68.2± 8,48Ч106) MMSCs endolumbal injection of 2.7-8.0Ч106 (mean 6.34±0.72Ч106) neuroinduced MMSCs did non induced in patients unfovarable reactions an complications. Moreover, during 3-11 months of monitoring 5 of 10 patients demonstrated decrease the frequency or disappearance of seizures, severity the incidence of seizures. 2 patients demonstrated increase of cognitive functions, 2 patients – decrease the level of anxiety. We concluded that application of MMSC-base cellular therapy id safe and enable to facilitate seizure status in patients with drug-resistant symptomatic epilepsy.
About the Authors
F. P. Hlebokazov
Republic Mental Health Research Center, Minsk
Belarus
Belarus
T. V. Dоkukina
Republic Mental Health Research Center, Minsk
Belarus
Belarus
S. I. Ighnatenko
Republic Transfusion and Medical Biotechnology Research Center, Minsk
Belarus
Belarus
S. M. Кosmacheva
Republic Transfusion and Medical Biotechnology Research Center, Minsk
Belarus
Belarus
N. V. Goncharova
Republic Transfusion and Medical Biotechnology Research Center, Minsk
Belarus
Belarus
M. P. Potapnev
Republic Transfusion and Medical Biotechnology Research Center, Minsk
Belarus
Belarus
M. V. Makhrov
Republic Mental Health Research Center, Minsk
Belarus
Belarus
P. P. Korolevich
Republic Mental Health Research Center, Minsk
Belarus
Belarus
N. N. Misyuk
Republic Mental Health Research Center, Minsk
Belarus
Belarus
I. V. Grigorieva
Republic Mental Health Research Center, Minsk
Belarus
Belarus
S. A. Marchuk
Republic Mental Health Research Center, Minsk
Belarus
Belarus
References
1. Bizjuk A.P. Kompendium metodov nejropsihologicheskogo issledovanija. SPb. 2005. 400 s.
2. Blejher V.M., Kruk I.V., Bokov S.N. Klinicheskaja patopsihologija: Rukovodstvo dlja vrachej i klinicheskih psihologov. M.; Voronezh. 2006. 624 s.
3. Dermanova I.B. Diagnostika jemocionalno-nravstvennogo razvitija. Issledovanie trevozhnosti (Ch.D. Spilberger, adaptacija Ju.L. Hanin). SPb. 2002; 124-126.
4. Anovadiya A.P., Sanmukhani J.J., Tripathi C.B. Epilepsy: Novel thera-peutic targets. J. Pharmacology & Pharmacotherapeutics. 2012, 3 (2): 112-117.
5. Atoui R., Chiu R.C. J. Immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. Stem cells Translational Medicine. 2012; 1 (3): 200-205.
6. Bengzon J., Mohapel P., Ekdahl С.T., Lindvall O. Neuronal apoptosis after bries and prolonged seizures. Prog. Brain Res. 2002; 135:111-9.
7. de Boer H.M., Mula M., Sander J.W. The global burden and stigma of epilepsy. Epilep. Behav. 2008; 12: 540-546.
8. Dedeurwaerdere S., Friedman A., Fabene P.F., Mazarati A., Murashima Y.L., Vezzani A., Baram T.Z. Finding a better drug for epilepsy: anti-inflammatory targets. Epilepsia. 2012; 53 (7): 1113-1118.
9. Ess K.C. Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells. Experimental Biology & Medicine. 2013; 238: 308-314.
10. Holmes G.L. Effect of neural transplants on seizure frequency and kindling in immature rats following kainic acid. Dev Brain Res. 1991; 47-56.
11. Kobow K., Auvin S., Jensen F., Loscher W., Mody I., Potschka H. et al. Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia. 2012; 53 (11): 1868-1876.
12. ODonoghue M.F., Gooddridge D.M., Redhead K. at al. Assessing the psychosocial consequences of epilepsy: a community-based study. Br. J. Gen. Pract. 1999; 49 (440): 221-214.
13. Parent J.M., Murphy G.G. Epilepsia. 2008; 49 (5): 19-25.
14. Pretorius E., Bornman M.S. Сalcium-mediatet aponecrosis plays a central role in the pathogenesis of estrogenis chemical-induced neurotoxicity. Med Hypotheses. 2005; 65 (5): 893-904.
15. Roper S.N., Steindler D.A. Stem cells as a potential therapy for epilepsy. Experimental Neurology. 2013; 244: 59-66.
16. Shakhbazau A., Shcharbin D., Seviaryn I., Goncharova N., Kosmacheva S., Potapnev M., Gabara B., Ionov M., Bryszewska M. Use of polyamidoamine dendrimera to engineer BDNG-producing human mesenchymal stem cells. Molecular Biology Reports. 2010; 37 (4): 2003-2008.
17. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983; 67 (6): 361-370.
Review
For citations:
Hlebokazov F.P., Dоkukina T.V., Ighnatenko S.I., Кosmacheva S.M., Goncharova N.V., Potapnev M.P., Makhrov M.V., Korolevich P.P., Misyuk N.N., Grigorieva I.V., Marchuk S.A. OUR EXPERIENCE IN APPLICATION OF AUTOLOGOUS BONE-MARROW-DERIVED MESENCHYMAL STEM CELLS FOR THERAPY OF PATIENTS WITH SYMPTOMATIC EPILEPSY. Epilepsy and paroxysmal conditions. 2014;6(1):6-14. (In Russ.)
Views:
636
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
